How do you pay?

How to pay the least

Ask for the cash price

Zykadia

We didn’t find one.

  1. Ask your pharmacy for Zykadia’s cash price, and one or two other pharmacies too.
  2. Zykadia’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Novartis Patient Assistance Foundation (NPAF). Patients must have a household income of less than or equal to $81,760 (for a household size of two) to be considered for NPAF. Or call 1-800-277-2254.

See if you qualify 

Compare every option

Question
Brand nameZykadia
Authorized genericceritinib
Regular genericceritinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Zykadia?
The original
–
–

Brand nameThe maker’s card

Novartis Oncology Universal Co-pay Program

Savings card from Novartis

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $25 a prescription

The card takes up to $15,000 a year off your co-pay.

Sign up on copay.novartisoncology.com 

Or call 1-877-577-7756.

In the maker’s words

“Patients are responsible for up to the first $25 (specific offer varies by brand) and Novartis pays up to $15,000 per calendar year.”

From the maker’s offer on copay.novartisoncology.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Zykadia itself, from the same company, sold without the brand name, and usually for less. For now Zykadia is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ZYKADIA is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Source: the FDA label for Zykadia (Novartis Pharmaceuticals Corporation), December 15, 2025. Full label on DailyMed 

Good to know